Short Interest in VolitionRX Ltd (VNRX) Rises By 80.3%

Share on StockTwits

VolitionRX Ltd (NYSEAMERICAN:VNRX) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 327,999 shares, a growth of 80.3% from the December 14th total of 181,885 shares. Based on an average daily volume of 113,840 shares, the short-interest ratio is presently 2.9 days. Approximately 1.5% of the company’s stock are short sold.

Shares of NYSEAMERICAN VNRX opened at $2.33 on Friday. VolitionRX has a 1 year low of $1.44 and a 1 year high of $4.00.

VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings results on Wednesday, November 7th. The medical research company reported ($0.14) EPS for the quarter, hitting analysts’ consensus estimates of ($0.14).

An institutional investor recently bought a new position in VolitionRX stock. Leisure Capital Management purchased a new position in VolitionRX Ltd (NYSEAMERICAN:VNRX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 72,479 shares of the medical research company’s stock, valued at approximately $188,000. Leisure Capital Management owned about 0.21% of VolitionRX at the end of the most recent quarter.

Separately, Oppenheimer set a $5.00 target price on shares of VolitionRX and gave the stock a “buy” rating in a research note on Friday, November 9th.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4071653/short-interest-in-volitionrx-ltd-vnrx-rises-by-80-3.html.

VolitionRX Company Profile

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.

Featured Article: Short Selling – Explanation For Shorting Stocks

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Biocept  Shares Gap Down to $1.67
Biocept Shares Gap Down to $1.67
VirnetX  Shares Gap Up to $6.33
VirnetX Shares Gap Up to $6.33
Zacks: Brokerages Anticipate Repligen Co.  Will Post Quarterly Sales of $50.33 Million
Zacks: Brokerages Anticipate Repligen Co. Will Post Quarterly Sales of $50.33 Million
Stealth 24-Hour Volume Tops $138.00
Stealth 24-Hour Volume Tops $138.00
Molecular Future  1-Day Volume Tops $421,889.00
Molecular Future 1-Day Volume Tops $421,889.00
Deutsche Lufthansa AG  Receives Consensus Recommendation of “Hold” from Brokerages
Deutsche Lufthansa AG Receives Consensus Recommendation of “Hold” from Brokerages


Leave a Reply

© 2006-2019 Ticker Report